Regeneus Ltd

ASX:RGS ISIN:AU000000RGS6

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.

 
      
    

查看其它语言版本

新闻

亚洲证券市场报告 2015年11月26日 - Regeneus Ltd (ASX:RGS)开始犬类癌症疫苗试验

🕔11/26/2015 10:13:55 AM 19140

Regeneus (ASX:RGS), 一家临床阶段再生医药公司,今天宣布开始其犬类癌症疫苗技术Kvax试验,结合化学疗法治疗犬类淋巴瘤。

阅读全文
###

234,225 公司背景浏览

  • 本页浏览人次: (过去7日: 60) (过去30日: 258) (自发布以来: 27261) 

公司详细信息

    总部
  • 2 Paddington Street
    Paddington NSW 2021
    Australia
  • 电话
  • +61-2-9499-8010 
  • 传真
  • +61-2-9499-8020 
  • 主要部门
  • 医疗-制药 
  • 支柱产业
  • 生物科技 
  • 主页
  • www.regeneus.com.au
  • E:
  • info@regeneus.com.au

更多新闻纪录

  • 2024/04/08: Proposed issue of securities - RGS*
  • 2024/04/08: Ceasing to be a substantial holder - Kirman 2*
  • 2024/04/08: Ceasing to be a substantial holder - Lee*
  • 2024/04/08: Ceasing to be a substantial holder - Vesey*
  • 2024/04/08: Change of Company Name and ASX Code*
  • 2024/04/05: Cambium Bio Raises A$3.48 Million in Strategic Placement*
  • 2024/04/05: Final Director's Interest Notice - Leo Lee*
  • 2024/04/05: Director Resignation - Leo Lee*
  • 2024/04/05: Notice of initial substantial holder*
  • 2024/04/05: Initial Director's Interest Notice - Waller*
*refer to company website

财务报告

下载年报

社会化媒体